KIT and neoplasm: In a mouse colon-26 tumor model, inhibition of receptor tyrosine kinase KIT enhances the anti-tumor activity of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1) by selectively reducing immunosuppressive M-MDSC clusters [54].